
Anchit Khanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11704160/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer. Journal of the National Cancer Institute, 2009, 101, 793-805.	6.3	186
2	Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target. Cancer Research, 2013, 73, 6548-6553.	0.9	135
3	Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1. Cancer Discovery, 2013, 3, 182-197.	9.4	117
4	DNA Damage in Cancer Therapeutics: A Boon or a Curse?. Cancer Research, 2015, 75, 2133-2138.	0.9	112
5	ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells. PLoS ONE, 2011, 6, e17979.	2.5	57
6	Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers. International Journal of Cancer, 2016, 138, 525-532.	5.1	53
7	Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells. Cancer Research, 2013, 73, 6757-6769.	0.9	41
8	CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget, 2015, 6, 19661-19670.	1.8	26
9	Constitutive CHK1 Expression Drives a pSTAT3–CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth. Molecular Cancer Research, 2020, 18, 709-722.	3.4	15
10	Assessment of the Potential of Pathological Stains in Human Prostate Cancer. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, 124-8.	0.8	2
11	Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cells. F1000Research, 0, 2, 174.	1.6	1
12	Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cellsÂ. F1000Research, 0, 2, 174.	1.6	0
13	Keeping GBM in check by targeting CHK1-CIP2A axis Journal of Clinical Oncology, 2014, 32, 2036-2036.	1.6	0